Pre-treatment prediction of response to peginterferon plus ribavirin in chronic hepatitis C genotype 3

Table 2 Association between pre-treatment characteristics and sustained virological response - univariate analyses n (%)

	SVR (n = 62)	No-SVR (n = 45)	OR	95%CI	P
Age, yr (mean ± SD)1	47.8 (± 9.1)	47.1 (± 8.3)	1	0.965-1.055	0.696
Male	61.3 (38)	77.8 (35)	0.425	0.190-1.079	0.093
INFL3 polymorphism CC2	31.4 (11)	24.1 (7)	1.44	0.475-4.372	0.585
3HCV-RNA ≥ 600000 UI/mL	44.1 (26)	70.5 (31)	0.33	0.145-0.755	0.009
Pre treatment elevated ALT4	86.7 (52)	90.9 (40)	0.65	0.183-2.312	0.553
Advanced fibrosis56	26.7 (16)	59.5 (25)	0.247	0.107-0.573	0.001
Steatosis	46.8 (29)	48.9 (22)	0.919	0.426-1.981	0.847
BMI (kg/m2) > 27	46.8 (29)	64.4 (29)	0.422	0.149-0.892	0.033
Diabetes	2 (1)	11 (5)	0.131	0.015-1.165	0.08
Peginterferon alfa 2a	75.8 (47)	75.6 (34)	0.986	0.403-2.413	1
RBV fix-dose7	64.5 (40)	62.2 (28)	1.104	0.498-2.447	0.841
80/80/80 adherence8	95.2 (59)	93.3 (42)	0.75	0.113-2.552	0.919

¹Available for 105 patients;

²Available for 64 patients;

³Available for 103 patients;

⁴Available for 104 patients;

⁵Advanced fibrosis includes patients with METAFIR F3 and cirrhosis;

⁶Available for 102 patients;

⁷800 mg/d;

⁸Patients received at least 80% of the peginterferon and RBV doses, and completed at least 80% of the expected treatment duration. ALT: Alanine aminotransferase; HCV: Hepatitis C virus; RBV: Ribavirin; BMI: Body mass index; SVR: Sustained virological response.